Dr Benjamin Angel Foundation

The Dr Benjamin Angel Foundation, a UK-registered grant-making charity established in 2006, honours the memory and values of Dr Benjamin Angel through targeted support for charitable relief, educational, and medical initiatives that reflect his legacy. Governed by six family-associated trustees under strict Charity Commission compliance, it prioritises making tangible impacts in the Jewish community, Israel, and medical fields, while selectively funding aligned causes elsewhere. Its discretionary, invitation-only approach—rooted in trustee judgment rather than open calls—emphasises excellence, strategic leadership, and sustained change, drawing from investment income and legacies for long-term resilience.

The Foundation funds medical research, higher education, and Jewish philanthropic projects, with recent grants to organisations like the Hebrew University in Jerusalem and Jnetics (focusing on genetic screening in UK Jewish communities). It supports charitable projects, programme costs, and core activities for reputable beneficiaries demonstrating direct relevance to Jewish welfare, health innovation, and education, often bridging UK-Israel interests with international flexibility when tied to the founder's vision.

Eligible entities are UK-registered charities and academic institutions of medium to large scale with proven track records; smaller grassroots groups are rarely supported, and there are no formal income thresholds or geographic base restrictions, though priorities centre on UK, Israel, and Jewish communities worldwide. Grants typically range from £10,000 to £75,000 (up to £100,000+ for strategic partners), awarded via annual trustee meetings with no public deadlines or application processes—unsolicited proposals are not accepted, requiring direct trustee engagement.

Distinctively family-stewarded and highly selective, it excludes individuals, capital appeals, and unaligned causes, setting it apart through its legacy-driven focus, transnational Jewish-medical nexus, and absence of guidelines, making trustee-identified alignment essential for prospects.